Overview

Topotecan in Treating Patients With Recurrent Brain Tumors

Status:
Completed
Trial end date:
2009-12-21
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of topotecan in treating patients with recurrent brain tumor.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
NCIC Clinical Trials Group
Treatments:
Topotecan
Criteria
DISEASE CHARACTERISTICS: Histologically proven recurrent anaplastic oligodendroglioma or
anaplastic mixed oligoastrocytoma following primary surgery and radiation therapy Tumors
for anaplastic mixed oligoastrocytoma must contain at least 25% oligodendroglial elements
Tumors must be clinically aggressive for patients with only 1 anaplastic feature Prior low
grade oligodendrogliomas or oligoastrocytomas undergoing repeat biopsy following clinical
or radiological progression are eligible Bidimensionally measurable and progressive lesions
by CT or MRI

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-3 Life expectancy: Not
specified Hematopoietic: Absolute granulocyte count at least 1,500/mm3 Platelet count at
least 100,000/mm3 Hepatic: Not specified Renal: Creatinine normal Other: Not pregnant or
nursing Fertile patients must use effective contraception No prior malignancies except
curatively treated carcinoma in situ of the cervix or nonmelanoma skin cancer No other
serious illness or medical condition No active uncontrolled infection No history of
neurologic or psychiatric disorder

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 6 weeks
since chemotherapy No more than 1 prior chemotherapy regimen No prior camptothecin
derivatives Endocrine therapy: At least 2 weeks on stable steroid therapy, if necessary
Radiotherapy: At least 2 months since prior radiotherapy No prior radiation therapy for
recurrent disease Surgery: At least 6 weeks since prior surgery (except biopsy only) Prior
surgery for recurrent disease allowed (including stereotactic biopsy or partial resection)
Other: No concurrent experimental drugs or anticancer therapy